Current and Emerging Drug Delivery Needs in Oncology
PharmaTalkRadio
English - June 04, 2018 15:00 - 59 minutes - 53.1 MB - ★★★★ - 16 ratingsScience pharmaceutical biotech clinical trials patient engagement immuno-oncology drug delivery r&d Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Drug Delivery Needs in Oncology
Due to the increasing number of parenteral biologic therapies that are administered intravenously, the already high pressure on infusion capacity and healthcare resources is expected further increase. A change from intravenous to subcutaneous dosing has been shown to reduce dosing complexity and overall drug administration related costs. There is keen interest in technologies that facilitate subcutaneous administration and potentially enable drug administration in the home setting.
Led by: Beate Bittner, PhD
Portfolio Strategy Director, Roche
Panelists: Panel: H Janice Adkins, MBA
Associate Director Marketing, BD Medical The exp Pharmaceutical Systems, North America EMEA
Ulrich Bruggemann
Head Academics and Innovation, Global Medical Devices of the Development, Sanofi US
Shawn Davis, PhD
Director, Technology Strategy and Innovation, Amgen
Declan Reilly
Section Head, Device Engineering, Device Development PTDE-D, Roche
Andrew J Yee, MD Medical Oncologist, Massachusetts General Hospital Cancer Center
This presentation took place at the 7th Annual Partnership Opportunities in Drug Delivery (PODD) 2017.